REPLY: Early Intravenous Beta-Blockade Before Primary Percutaneous Coronary Intervention Gives Major Benefits Apparently Without Side Effects
We appreciate the comment by our admired Professor Opie regarding the potential side effects of early intravenous (IV) beta-blockers in patients with ST-segment elevation myocardial infarction (STEMI).
Our paper described the long-term follow-up of patients in the METOCARD-CNIC (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction) trial (1) . The acute effects of IV metoprolol in this trial were reported in a previous publication (2) . In the first publication, we described the incidence of adverse events during admission (those that can be ascribed to an acute single administration of IV metoprolol before primary angioplasty): death during admission (2.1% vs. 2.3% in IV metoprolol vs. control, respectively), advanced atrioventricular block (0.7% vs. 1.5%), cardiogenic shock (4.3% vs. 5.4%), and ventricular tachycardia/fibrillation (3.6% vs. 7.7%).
Thus, it is not correct that there were no side effects of beta-blockade in our study; rather, we presented that metoprolol was not associated with an excess number of these side effects.
The role of early IV beta-blockade in STEMI was mostly evaluated long ago, and the side effect profile has been dramatically changed within the last few years. The METOCARD-CNIC trial was the first ran- 
